Crimean-Congo Hemorrhagic Fever (CCHF), among the high-priority pathogens because of its high case fatality rate and its potential for nosocomial outbreaks and the subsequent difficulties in treatment and prevention. For the last four decades, the virus has repeatedly caused an endemic in many parts of the world including Pakistan, Iran and India. Though this virus is responsible for relatively low numbers of human casualties, it is up to 80% fatal in the clinically infected patients. The availability of present diagnostic techniques is not enough for timely rescue of CCHF infected patients. The progressive work for the development of new rapid specific and reliable diagnostic tests is the need of time for the infected patient. At present Ribavirin drug is available to the clinicians as recommended therapeutic intervention. The efforts to include the other drugs like favipiravir may also be continued for its clinical efficacy and safety. Currently no safe and effective vaccine is available either for human or animal use that can prevent this disease. The development of vaccines in line with the requirement of Targeted Product Profile (TPP) as per the standards of Food and Drug Administration (FDA) is essentially needed. We discuss the techniques used in the preparation of different vaccines concerning their success and failures. In this review, we also discuss epidemiology, diagnosis, treatment and prevention in the light of recent global advances.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.